This phaseII interventional trial (n=40), titled "MDMA-Assisted Cognitive Behavioral Therapy (CBT) Compared With Methamphetamine-Assisted CBT in Obsessive-Compulsive Disorder (OCD): A Phase II Study," aims to assess the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).
Status: Not yet recruiting
Start date: 2023-12-01
Phase II
Blinded
40 participants
Interventional
This observational cohort study (n=140) aims to assess the safety and tolerability of ketamine treatment in adult patients suffering from various mental health conditions, including major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and others.
Status: Enrolling by invitation
Start date: 2022-09-01
Not Applicable
Open
140 participants
Observational
This open-label clinical trial (n=10) evaluates the feasibility, clinical effects, and safety of psilocybin-assisted psychotherapy (25mg, 2x) for treatment-resistant obsessive-compulsive disorder (OCD).
Status: Not yet recruiting
Start date: 2024-04-01
Phase I
Open
10 participants
Interventional
This single-group assignment trial (n=20) assesses the impact of psilocybin on cognitive inflexibility and neural plasticity in individuals with obsessive-compulsive disorder (OCD).
Status: Recruiting
Start date: 2022-10-28
Phase I
Open
20 participants
Interventional
This single-blind study (n=20) investigates the enduring effects of psilocybin (10mg, 2x) on OCD symptoms, focusing on the activation of the 5-HT2A receptor and its impact on behavioural deficits associated with OCD.
Status: Recruiting
Start date: 2022-09-07
Blinded
20 participants
Interventional
This double-blind, randomised controlled trial (n=40) aims to investigate the efficacy of psychedelic therapy using psilocybin and MDMA in treating treatment-resistant Obsessive-Compulsive Disorder (OCD) in adults.
Status: Not yet recruiting
Start date: 2023-08-01
Phase II
Blinded
40 participants
Interventional
This Phase II parallel assignment interventional trial (n=150) is conducted by Stanford University. The study aims to comprehend how ketamine functions in the brain to reduce symptoms of Obsessive-Compulsive Disorder (OCD).
Status: Recruiting
Start date: 2024-02-24
Phase II
Blinded
150 participants
Interventional
This interventional trial (n=40) seeks to explore the potential for psychedelic therapy using psilocybin and MDMA to improve symptoms of treatment-resistant obsessive-compulsive disorder (TR-OCD).
Status: Not yet recruiting
Start date: 2023-08-01
Phase II
Blinded
40 participants
Interventional
This randomized, double-blind, comparator-controlled cross-over trial (n=30) will investigate the therapeutic efficacy of low dose ketamine in patients with Obsessive-Compulsive Disorder (OCD) at the Medical University of Vienna.
Status: Recruiting
Start date: 2022-08-01
Not Applicable
Blinded
28 participants
Interventional
This study will test the feasibility, safety, and evidence for the efficacy of psilocybin administration in participants with obsessive-compulsive disorder (OCD).
Status: Not yet recruiting
Start date: 2022-09-30
Phase I
Open
30 participants
Interventional
This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD.
Status: Not yet recruiting
Start date: 2022-11-01
Phase I
Blinded
30 participants
Interventional
This study aims to investigate the effects of oral psilocybin on OCD symptomatology and provide the first evidence of the neural mechanism that may mediate psilocybin's purported therapeutic effects on OCD.
Status: Recruiting
Start date: 2018-11-13
Phase I
Blinded
30 participants
Interventional
In this pilot study, 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Follow-up visits to monitor safety and clinical outcome will be conducted over a 3 month period.
Status: Completed
Start date: 2021-2-26
Phase II
Open
12 participants
Interventional
The purpose of the current study is to explore new alternative options for the treatment of OCD that can widely and continuously benefit patients. Specifically, the aim of this study is to investigate the feasibility, safety and efficacy of psilocybin-assisted psychotherapy for treatment of severe OCD.
Status: Not yet recruiting
Start date: 2021-1-12
Phase I
Open
15 participants
Interventional
This retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.
Status: Enrolling by invitation
Start date: 2019-12-3
Open
260 participants
Observational
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it works.
Status: Recruiting
Start date: 2019-1-2
Phase I
Blinded
15 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
?>